Soligenix, Inc. announced that it has extended its development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax™ drug substance protein antigen. This specific agreement will build upon process development work conducted to date in support of manufacturing scale-up that will eventually be performed in accordance with current good manufacturing practices (cGMPs) at Emergent's manufacturing facility located in Baltimore, MD. Soligenix has been developing RiVax™, in conjunction with its heat stabilization technology, ThermoVax®, as a heat-stable biodefense vaccine.